EUVIMED · CrossrefZeitschrift
BioProcessing Journal
ISSN 1538-8786 · Bio Processing Journal
Neueste Artikel
Computational Analysis of Mixing Performance and Hydrodynamic Stress in a 30,000 L Bioreactor
White Paper – Continuous Mapping in Life Sciences: A Practical Framework for GxP Compliance
From the Publisher: Big Companies Have Lots of Money -- Just Not for Operations
From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?
From the Editor-in-Chief: The Biotech Industry Continues to Improve
From the Editor-in-Chief: Applying More Automation to Our BioProcessing
From the Editor-in-Chief: Good News! The Licensure of Biologics is Really Taking Off
From the Editor-in-Chief: Biomedical Research and Biopharmaceutical Advances in Cuba
From the Editor-in-Chief: A "Renaissance" of Sorts Within the Biologics Industry
From the Editor-in-Chief: Major Successes in the Industry and Primary Challenges That Follow
From the Editor-in-Chief: Production Technology for Lentiviral Vectors
From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce
From the Editor-in-Chief: I Still Don't Like Calling Biopharmaceuticals "Drugs"
From the Publisher: Regulations, Freedoms, and Money
From the Publisher: Small Biotech Companies are a Big Deal
From the Editor-in-Chief: Downstream Processing in Paradise
From the Editor-in-Chief: Flexible Facilities and Systems
From the Editor-in-Chief: What Was Your Name Again?
From the Editor-in-Chief: The Beneficial "Spin-Out" Business Model
From the Editor-in-Chief: "Therapeutic Glyco-Proteins Produced by Living Organisms" or "Drugs"?
From the Editor-in-Chief: Stem-to-Stern, Continuous Process for Biologics?
From the Editor-in-Chief: The Best ROI -- Employee Training and Career Development
From the Editor-in-Chief: Innovative Small Companies
From the Editor-in-Chief: Building Businesses and Developing Strategic Partnerships
From the Publisher: The Development and Production of Biologics, Plus Addressing the Needs of the FDA
From the Publisher: The Biotech Industry's "Growth Through Acquisition" Trend
From the Publisher: Fewer Biologics Companies and the Desired Number of New Products Hasn't Materialized
From the Publisher: Biosimilars, Biogenerics, or Follow-On Biologics to Licensed Materials
From the Publisher: Best Corporate Practices for the Biotech Industry
Gamma Irradiation of Animal Serum: Theoretical Basis of Impacts of Gamma Irradiation on Biological and Synthetic Polymers
EUVIMED